James Krocak

Overview

Gender
male

James Krocak is a healthcare technologist and serial entrepreneur, who founded Theraone and Quantitative Insights and helped build the scientific teams at Sutro Biopharma. While at these companies, James facilitated strategic collaborations with large and small medical device and pharmaceutical companies, participated in >$60 million of external financing, and was a NSF Principal Investigator. Outside of raising capital, James brought a distinct business vision to these companies, enabling him to win the 2010 Chicago Biomedical Consortium Business Plan Competition as well as the “Best Business Plan” at the 2011 Rice Business Plan Competition. While at these companies, James was invited speaker at 14 international conferences and was author on several scientific articles and patents.

Outside of building companies, James has notable experience within the venture capital community, with work at Foundation Capital, Hyde Park Angels, and elsewhere. At these firms he has personally screened >500 investment opportunities, and led due diligence into 6 early-stage financings in the healthcare and technology sectors worth >$10 million. James was a member of the charter class of Young Entrepreneurs at Foundation Capital, and recently won Chicago Booth’s Venture Capital Investment Competition (VCIC), the Mountain Regional VCIC, and took 2nd place at the International VCIC Finals.
James holds a BChE with honors and distinction in chemical engineering from the University of Minnesota, where he was a NSF fellow, a MS in chemical engineering from the University of California, Berkeley, where he was a NIH and Management of Technology Fellow, and an MBA with honors from the University of Chicago Booth School of Business, where he was the O’Brien Fellow.

Jobs

Number of Current Jobs
1
James Krocak has 1 current jobs including Senior Director, Insights and Analytics, US Oncology at AstraZeneca , .
Organization Name Title At Company Start Date End Date
AstraZeneca Senior Director, Insights and Analytics, US Oncology Nov 1, 2019 Detail